GlassScriptPhysician profile
Patrick Joseph Stickle
NPI 1457021289
$4,842.96
in general payments reported to CMS, 2019-2025
20 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,072 · 2023: $1,063 · 2024: $1,190 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,013 · Education: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,013.05 |
| Education | $757.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,194.50 | 2022-2025 | Ilumya, Winlevi |
| Abbvie INC. | $675.65 | 2022-2025 | |
| Ucb, INC. | $553.34 | 2022-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $478.82 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $388.55 | 2022-2025 | |
| Leo Pharma INC. | $248.84 | 2024-2025 | Adbry, Anzupgo |
| Incyte Corporation | $200.01 | 2023-2024 | Opzelura |
| Sanofi-Aventis U.S. LLC | $178.98 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $175.19 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $152.03 | 2022-2025 | |
| Pfizer INC. | $100.96 | 2022-2025 | |
| Eli Lilly and Company | $99.00 | 2025 | |
| Galderma Laboratories, L.P. | $79.55 | 2022-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $78.01 | 2025 | Dupixent |
| Janssen Biotech, INC. | $73.63 | 2022-2025 | Tremfya |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $60.79 | 2024 | |
| Amgen INC. | $39.50 | 2022 | |
| Dermavant Sciences, INC. | $29.30 | 2024 | Vtama |
| Paratek Pharmaceuticals, INC. | $20.55 | 2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.76 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Stickle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.